주 메뉴 바로가기 본문 바로가기 하단 바로가기

Company

Celltrion, leading the Korean biopharmaceutical industry.

About Us

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.

Vision

We aim to become a global pharmaceutical company that promotes health and welfare for all by developing next-generation biopharmaceutical and small molecule pharmaceutical products.

Core Values
Creativity
We solve problems by thinking outside the box.
Principle
We value principles, faith and trust.
Challenge
We meet challenges head-on and continuously look for challenges others are reluctant to take on.
Global No. 1
We emphasize top-tier expertise and competitiveness to lead the global market.
At a Glance
World’s First

Antibody
Biosimilar

No. of Employees

2,145

Revenue

USD 153 Billion

Domestic biologics production&export

1st

Sales Permits in

More than 90 countries

Production Capacity

190,000 liters